Drug Profile
Research programme: Lysosomal storage disease therapeutics - bioOasis/Takeda
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Shire
- Developer biOasis Technologies; Shire
- Class Drug conjugates; Enzymes
- Mechanism of Action Biological transport stimulants; Enzyme replacements; Transferrin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lysosomal storage diseases
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for research development in Lysosomal storage diseases in Canada (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Lysosomal storage diseases in USA (Parenteral)